Side-by-side · Research reference

EpitalonvsTB-500

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/37 cited

BPhase 2Reviewed8/46 cited

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

01Mechanism of Action

Parameter

Epitalon

TB-500

Primary target

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Pathway

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

Downstream effect

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Feedback intact?

—

Endogenous protein at baseline; supplementation amplifies

Origin

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Antibody development

—

02Dosage Protocols

Parameter

Epitalon

TB-500

Standard dose

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

Frequency

Once daily during a cycle

2× per week (loading); then 1× per week (maintenance)

Lower / starter dose

2.5 mg / day

1 mg per injection

Evidence basis

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Duration

10–20 day cycles, 1–2× per year

4–8 weeks loading; longer maintenance for chronic injury

Reconstitution

Bacteriostatic water

Bacteriostatic water, 1–2 mL per 5 mg vial

Timing

Pre-sleep preferred (pineal alignment)

Evening or pre-rest preferred (anecdotal)

Half-life

Hours (estimated)

~2 hours (estimated; tissue uptake longer)

04Side Effects & Safety

Parameter

Epitalon

TB-500

Injection site reaction

Mild irritation

Mild erythema, transient pain

Sleep architecture

Improved subjective sleep quality (anecdotal)

—

Cancer risk

Theoretical via telomerase activation in pre-malignant cells

Theoretical via angiogenesis pathway

Long-term safety

Limited Western RCT data

Unknown beyond Phase 2

Pregnancy / OB

Avoid

Antibody formation

Not reported

No data (no long-term human trials)

GI symptoms

—

Rare nausea (anecdotal)

Lethargy / fatigue

—

Reported anecdotally during loading phase

Absolute Contraindications

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Relative Contraindications

Epitalon

·Family history of cancer

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

05Administration Protocol

Parameter

Epitalon

TB-500

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

2. Injection site

SQ — abdomen preferred. Rotate sites.

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

3. Timing

Pre-sleep preferred to align with pineal axis.

Evening or pre-sleep is most common anecdotal timing.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

5. Needle

29–31G, 4–8 mm insulin syringe.

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

Epitalon

— no documented stacks

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair